[A22-117] Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.02.2023
Commission awarded on 31.10.2022 by the Federal Joint Committee (G-BA).
Maintenance therapy of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose tumour is associated with HRD-positive status
- Patients without detectable tumour after primary surgery and patients without detectable tumour/with complete response following chemotherapy: indication of considerable added benefit
- Patients without detectable tumour after interval surgery and patients with partial response: indication of lesser benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.